Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 77.55% is 134% above its 5-year average of -229.66%, near the high end of its 5-year range (-1245.76%–77.55%).
133.34% above its 12-month average of -232.61%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-05-31): 57.43%.
GROSS MARGIN
77.55%
GROSS MARGIN AVG TTM
-232.61%
GROSS MARGIN AVG 3Y
-157.00%
GROSS MARGIN AVG 5Y
-229.66%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+133.34%
CURRENT VS 3Y AVG
+149.40%
CURRENT VS 5Y AVG
+133.77%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.82%
median of 737 covered companies
CURRENT VS SECTOR MEDIAN
+89.98%
vs the sector median at left
Nurix Therapeutics, Inc.
Market Cap
$2.36B
Gross Margin
77.55%
TTM Avg
-232.61%
3Y Avg
-157.00%
5Y Avg
-229.66%
Market Cap
$2.38B
Gross Margin
56.20%
TTM Avg
28.10%
3Y Avg
28.10%
5Y Avg
28.10%
Market Cap
$2.34B
Gross Margin
92.48%
TTM Avg
74.82%
3Y Avg
78.80%
5Y Avg
76.59%
Market Cap
$2.38B
Gross Margin
64.71%
TTM Avg
54.44%
3Y Avg
41.55%
5Y Avg
20.41%
Market Cap
$2.41B
Gross Margin
18.57%
TTM Avg
22.55%
3Y Avg
18.71%
5Y Avg
13.63%
Market Cap
$2.30B
Gross Margin
75.42%
TTM Avg
77.61%
3Y Avg
78.83%
5Y Avg
79.96%
Market Cap
$2.44B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$2.28B
Gross Margin
17.98%
TTM Avg
29.88%
3Y Avg
47.29%
5Y Avg
57.26%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.36B | 77.55% | -232.61% | -157.00% | -229.66% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.38B | 56.20% | 28.10% | 28.10% | 28.10% |
| Liquidia Corporation (LQDA)vs › | $2.34B | 92.48% | 74.82% | 78.80% | 76.59% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.38B | 64.71% | 54.44% | 41.55% | 20.41% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | 18.57% | 22.55% | 18.71% | 13.63% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.30B | 75.42% | 77.61% | 78.83% | 79.96% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.44B | -61.96% | -19.42% | -14.39% | 23.74% |
| Disc Medicine, Inc. (IRON)vs › | $2.44B | 0.00% | 0.00% | 0.00% | 0.00% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | 17.98% | 29.88% | 47.29% | 57.26% |
| Privia Health Group, Inc. (PRVA)vs › | $2.58B | 7.61% | 10.03% | 9.93% | 9.40% |
Gross Margin
77.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-05-31 | 57.43% |
| 2026-02-28 | -1245.76% |
| 2025-11-30 | 65.89% |
| 2025-08-31 | 36.66% |
| 2025-05-31 | -77.27% |
| 2025-02-28 | -277.52% |
| 2024-11-30 | -406.05% |
| 2024-08-31 | -340.75% |
| 2024-05-31 | -304.58% |
| 2024-02-29 | -201.51% |
| 2023-11-30 | -227.94% |
| 2023-08-31 | -159.14% |
| 2023-05-31 | -49.18% |
| 2023-02-28 | -261.18% |
| 2022-11-30 | -579.73% |
| 2022-08-31 | -342.60% |
| 2022-05-31 | -315.44% |
| 2022-02-28 | -348.36% |
| 2021-11-30 | -393.93% |
| 2021-08-31 | -201.46% |
| 2021-05-31 | -266.58% |
| 2021-02-28 | -359.05% |
| 2020-11-30 | -205.65% |
| 2020-08-31 | -363.62% |
| 2020-05-31 | -238.16% |
| 2020-02-29 | -352.76% |
| 2019-11-30 | -588.72% |
| 2019-08-31 | -4.05% |
| 2019-05-31 | -13.98% |
| 2019-02-28 | -13.00% |
